Physician

Daniel Paul Lupash, M.D.

According to 2025 Medicare claims, Daniel Lupash, M.D. (NPI: 1619154135) practices rheumatology in the Ogden, UT market, with the plurality of this provider's patient population coming from Weber, UT. This provider's primary affiliated billing organization is IHC HEALTH SERVICES, INC (NPI: 1396773834; TIN: 94-2854057) and primary practice location at 84403-3288. Lupash is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), MountainStar Care Partners ACO (ACO ID: A5181), and Castell Accountable Care, LLC (ACO ID: D0136), participating under both the MSSP and REACH models.

Lupash's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 184 traditional Medicare patients, billed 32,504 HCPCS/CPT codes, and received $661,852 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,267 prescription claims across 211 beneficiaries totaling $1,411,044 in drug costs, led by Enbrel (Etanercept). Open Payments data shows 1 records totaling $125. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $330,668 to $1,411,044. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	292	34,288	$765,103
2016	314	36,451	$920,846
2017	251	39,802	$1,078,951
2018	250	43,667	$1,184,469
2019	237	59,354	$1,394,146
2020	217	50,959	$1,176,878
2021	213	44,172	$1,089,128
2022	214	35,330	$886,650
2023	205	29,436	$732,915
2024	184	32,504	$661,852

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	174	1,108	$330,668
2016	179	1,144	$507,099
2017	152	1,021	$416,403
2018	163	1,084	$453,232
2019	168	1,105	$568,999
2020	177	1,048	$588,868
2021	162	948	$598,293
2022	162	948	$756,772
2023	161	1,031	$832,175
2024	211	1,267	$1,411,044

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	87	156	$129
96413	Administration of chemotherapy into vein, 1 hour or less	35	189	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	166	390	$81
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	110	220	$12
36415	Insertion of needle into vein for collection of blood sample	101	205	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel	Etanercept	31	1,316	$348,563
Enbrel Sureclick	Etanercept	35	1,204	$334,307
Rinvoq	Upadacitinib	16	480	$100,415
Orencia	Abatacept	14	392	$89,960
Humira Pen	Adalimumab	12	336	$76,255

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$125	UCB, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Paul Lupash, M.D.?

Tedicare shows public-source Medicare data for Daniel Paul Lupash, M.D. (NPI 1619154135), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Paul Lupash, M.D. have ACO affiliation data?

Daniel Paul Lupash, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), MountainStar Care Partners ACO (MSSP, ACO ID A5181), and Castell Accountable Care, LLC (REACH, ACO ID D0136).

What billing organization is linked to Daniel Paul Lupash, M.D.?

Daniel Paul Lupash, M.D. is linked to IHC HEALTH SERVICES, INC (billing NPI 1396773834) in the available physician profile data.

Does Daniel Paul Lupash, M.D. have Open Payments data?

Daniel Paul Lupash, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.